We evaluated the effect of ozagrel and darteparin after mitral valve repair under cardiopulmonary bypass in dogs. A total of 32 dogs were included in this study (9.7±2.3 years old, 5.3±3.7 kg). The two out of 32 cases were excluded because of death with aspiration or hypotension within 24 hours after surgery. Dogs (
n=14) were treated with hydrochloric acid ozagrel orally (p.o.) for a dose of 5 or 10 mg/kg BID, or Low molecular weight heparin; dalteparin (5 IU/kg/hr) after the operation. The dose of dalteparin was increased gradually (until 50 or 75 IU/kg/hr), and then changed to subcutaneous injection of 50–100 IU/kg/day for 6–12 days (
n=16). After that, ozagrel hydrochloride (10 mg/kg p.o., BID), a thoromboxane A 2 synthase inhibitor, was administered for 1 month instead of dalteparin. In this study, it was suggested there were less thrombosis in the darteparin-treated group. The number of platelets increased earlier in darteparin-treated group. Also, there was significant lower rate of hyperlipasemia in the darteparin-treated group. This study has shown the effect of darteparin in preventing adverse events, and it was emphasized the importance of anticoagulation management after mitral valve repair.
View full abstract